China Resources Boya Bio pharmaceutical Group Co 300294.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
14.02
-1.61%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Resources Boya Bio pharmaceutical Group Co
Its shares trade on Shenzhen under the ticker 300294.SZ. It has been listed since 8 March 2012. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.05bn and net income of CN¥112.7m. At that date it held total assets of CN¥8.63bn and shareholders' equity of CN¥7.44bn.
China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Mar 2012
- Employees
- 1,690
- Website
- china-boya.com ↗
Leadership
Pay as last reported
- Mr. Kai QiuChairman of the Board, since 2023
- Mr. Hui RenPresident, Director, since 2024CN¥93,000
- Mr. Yuxuan PanChief Financial Officer, Secretary of the Board, Director, since 2024
- Mr. Huacheng LiangVice President, Director, since 2021CN¥1.1m
- Mr. Shousun LiVice PresidentCN¥1.9m
- Mr. Qingsong LinVice President
- Mr. Shuanhong ZhangVice PresidentCN¥1.3m
- Mr. Peng LinDirector
- Ms. Yifei WangDirector
- Mr. Huasheng HuangIndependent DirectorCN¥200,000
- Mr. Weidong ZhangIndependent DirectorCN¥200,000
- Mr. Li ZhaoIndependent DirectorCN¥200,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 78
- Social
- 51
- Governance
- 16
- Direct emissions (scope 1)
- 3,975.47 t
- Energy emissions (scope 2)
- 26,077.4 t
- Women in the workforce
- 55.21156%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Resources Boya Bio employs 1,690 full-time employees in Fuzhou, Jiangxi.
- The company produces human albumin and immune globulin for tumor and liver disease treatment.
- It offers diabetic pharmaceuticals including metformin hydrochloride and glimepiride.
Weaknesses
- The firm's products are mainly distributed within the domestic market of China.
- Human fibrinogen and hepatitis B immune globulin are limited to specific medical applications.
- The company's IPO was in 2012, indicating a long-standing market presence.
Opportunities
- Expanding into international markets for blood products could increase global reach.
- New diabetic treatments like pioglitazone hydrochloride may attract more patients.
- The growing demand for hepatitis B immune globulin in China presents a market opportunity.
Threats
- Competition from other biotechnology firms in China's Health Care sector is increasing.
- Regulatory changes in China's pharmaceutical industry could affect product approvals.
- The domestic market focus may limit growth potential compared to global competitors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.